Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$36.5 - $52.5 $14,381 - $20,685
394 Added 1.18%
33,751 $1.66 Million
Q4 2023

Feb 13, 2024

BUY
$18.94 - $37.24 $80,987 - $159,238
4,276 Added 14.7%
33,357 $1.22 Million
Q3 2023

Nov 13, 2023

BUY
$23.12 - $31.38 $23,906 - $32,446
1,034 Added 3.69%
29,081 $672,000
Q2 2023

Aug 04, 2023

BUY
$23.15 - $32.71 $246,871 - $348,819
10,664 Added 61.35%
28,047 $735,000
Q1 2023

May 12, 2023

BUY
$24.97 - $34.05 $8,664 - $11,815
347 Added 2.04%
17,383 $447,000
Q4 2022

Feb 10, 2023

BUY
$21.73 - $28.72 $12,016 - $15,882
553 Added 3.35%
17,036 $443,000
Q3 2022

Nov 14, 2022

BUY
$24.1 - $39.66 $5,615 - $9,240
233 Added 1.43%
16,483 $470,000
Q2 2022

Aug 12, 2022

BUY
$18.36 - $60.07 $32,203 - $105,362
1,754 Added 12.1%
16,250 $400,000
Q1 2022

May 13, 2022

SELL
$48.97 - $65.46 $49,900 - $66,703
-1,019 Reduced 6.57%
14,496 $818,000
Q4 2021

Feb 11, 2022

SELL
$53.3 - $75.84 $24,784 - $35,265
-465 Reduced 2.91%
15,515 $962,000
Q3 2021

Nov 12, 2021

SELL
$62.66 - $88.26 $23,810 - $33,538
-380 Reduced 2.32%
15,980 $1.01 Million
Q2 2021

Aug 13, 2021

BUY
$67.45 - $85.63 $158,844 - $201,658
2,355 Added 16.82%
16,360 $1.35 Million
Q1 2021

May 07, 2021

BUY
$65.1 - $93.59 $2,408 - $3,462
37 Added 0.26%
14,005 $1.03 Million
Q4 2020

Feb 12, 2021

BUY
$48.36 - $77.92 $62,771 - $101,140
1,298 Added 10.24%
13,968 $1.01 Million
Q3 2020

Nov 04, 2020

SELL
$36.14 - $51.99 $10,408 - $14,973
-288 Reduced 2.22%
12,670 $604,000
Q2 2020

Aug 12, 2020

BUY
$22.98 - $48.57 $155,758 - $329,207
6,778 Added 109.68%
12,958 $544,000
Q1 2020

May 04, 2020

SELL
$20.44 - $41.21 $7,317 - $14,753
-358 Reduced 5.48%
6,180 $167,000
Q4 2019

Feb 05, 2020

BUY
$17.74 - $39.52 $115,984 - $258,381
6,538 New
6,538 $252,000

Others Institutions Holding SWTX

About SpringWorks Therapeutics, Inc.


  • Ticker SWTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,401,100
  • Market Cap $2.27B
  • Description
  • SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...
More about SWTX
Track This Portfolio

Track American International Group, Inc. Portfolio

Follow American International Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on American International Group, Inc. with notifications on news.